CCRM supports the commercialization of regenerative medicine-based technologies, and cell and gene therapies, with strategic funding, dedicated infrastructure and specialized business and scientific expertise.

By partnering with leading research institutions to launch new ventures, enabling industry by providing innovative contract development and manufacturing organization (CDMO) services through our CDMO subsidiary, OmniaBio Inc., and scaling emerging companies by catalyzing investment, CCRM is accelerating the translation of promising technologies, processes and therapies into life-changing health outcomes for patients.

Established in 2011, CCRM is a global public-private partnership headquartered in Canada that launched with seed funding from the Government of Canada, the Province of Ontario, and leading academic and industry partners. CCRM is now self-sustaining.

A network of researchers, leading companies, strategic investors and entrepreneurs, CCRM accelerates the translation of scientific discovery into new companies and marketable products for patients, with specialized teams, funding, and infrastructure. CCRM is the commercialization partner of Medicine by Design and is hosted by the University of Toronto.
Located in Toronto’s Discovery District, CCRM is in the heart of Canada’s premier health care innovation hub, and is surrounded by over 30 world-class clinical and research institutions. With access to more than 140,000 students and scientists in Toronto, CCRM is deeply interconnected in a thriving biomedical cluster.

A summary of CCRM’s first 10 years

In 2021, we celebrated our 10th anniversary. Catch up on the story of our first 10 years by reading “The CCRM story: 10 years in the making” in the digital INNOVATE Toronto booklet by clicking here to read it on the INNOVATE website. A visual of our story is below.